Table 1:
Participant Characteristics
| On Statin at A5321 Entry | ||||
|---|---|---|---|---|
| Yes (N=72) |
No (N=231) |
Total (N=303) |
P- Value* |
|
| Age at A5321 entry (years) | ||||
| Median (Q1 - Q3) | 53 (49 - 60) | 46 (39 - 53) | 48 (41 - 54) | <0.001 |
| Sex (% Male) | ||||
| 61 (85%) | 187 (81%) | 248 (82%) | 0.60 | |
| Race/Ethnicity | ||||
| White Non-Hispanic | 46 (64%) | 122 (53%) | 168 (55%) | 0.34 |
| Black Non-Hispanic | 10 (14%) | 51 (22%) | 61 (20%) | |
| Hispanic (Regardless of Race) | 14 (19%) | 52 (23%) | 66 (22%) | |
| Other | 2 (3%) | 6 (3%) | 8 (3%) | |
| Smoking (% cigarette smoker at A5321 entry) | ||||
| 15 (21%) | 55 (24%) | 70 (23%) | 0.64 | |
| Diabetes diagnosis prior to A5321 entry | ||||
| 10 (14%) | 7 (3%) | 17 (6%) | 0.002 | |
| Intravenous drug use at A5321 entry | ||||
| Current | 0 (0%) | 0 (0%) | 0 (0%) | 0.31 |
| Previous | 1 (1%) | 11 (5%) | 12 (4%) | |
| Never | 71 (99%) | 220 (95%) | 291 (96%) | |
| ARV Regimen at A5321 entry | ||||
| NNRTI-based | 45 (63%) | 113 (49%) | 158 (52%) | 0.22 |
| PI-based | 16 (22%) | 66 (29%) | 82 (27%) | |
| InSTI-based | 11 (15%) | 51 (22%) | 62 (20%) | |
| Other | 0 (0%) | 1 (0%) | 1 (0%) | |
| Years on ART at A5321 entry | ||||
| Median (Q1 - Q3) | 8.1 (6.6 - 12.3) | 7.3 (4.8 - 8.5) | 7.3 (6.1 - 10.1) | 0.002 |
| Pre-ART CD4+ T-cell count (cells/mm3) | ||||
| Median (Q1 - Q3) | 286 (110 - 414) | 254 (114 - 369) | 258 (113 - 374) | 0.27 |
| A5321 entry CD4+ T-cell count (cells/mm3) | ||||
| Median (Q1 - Q3) | 737 (542 - 935) | 665 (505 - 840) | 681 (515 - 864) | 0.038 |
| Pre-ART plasma HIV-1 RNA (log10cps/mL) | ||||
| Median (Q1 - Q3) | 4.6 (4.3 - 5.0) | 4.6 (4.2 - 5.0) | 4.6 (4.2 - 5.0) | 0.82 |
| A5321 entry HIV-1 RNA (cps/mL) | ||||
| <40 | 72 (100%) | 231 (100%) | 303 (100%) | |
| Statin at A5321 entry | ||||
| Simvastatin | 5 (7%) | 0 (0%) | 5 (2%) | |
| Pravastatin | 25 (35%) | 0 (0%) | 25 (8%) | |
| Atorvastatin | 27 (38%) | 0 (0%) | 27 (9%) | |
| Rosuvastatin | 14 (19%) | 0 (0%) | 14 (5%) | |
| Ezetimibe/Simvastatin | 1 (1%) | 0 (0%) | 1 (0%) | |
*
Exact Wilcoxon test for continuous variables; Fisher's Exact test for categorical variables.
ARV: Antiretroviral regimen; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; InSTI: Integrase strand transfer inhibitor; ART: Antiretroviral therapy